Vasa and colleagues first reported an increase in EPCs (CD34+/KDR+) and CACs out to 28 days in 40 patients with CAD.[33] Most recently, these results were replicated in a small cohort of patients initiated on Atorvastatin therapy, yielding a doubling of CD45dim/CD34+/KDR+ cells at four weeks.[34] While neither of these studies were randomized or had control groups for comparison, their results are very similar to those observed in the current study. Here, CD34 is linked to coronary artery disorder.